Roivant Sciences Ltd (ROIV) Stock Forecast & Analysis

Real-time stock price, financial statements, consensus target price, insider trading, and technical analysis for Roivant Sciences Ltd (ROIV:NASDAQ), powered by AI.

Current Price
$30.04
P/E Ratio
-126.7
Market Cap
21.8B
Sector
Healthcare
What is the Roivant Sciences Ltd stock price forecast?

Roivant Sciences Ltd is currently trading at $30.04. View real-time AI analysis on Alpha Lenz.

What is Roivant Sciences Ltd insider trading activity?

View the latest insider trading data for Roivant Sciences Ltd on Alpha Lenz.

What is Roivant Sciences Ltd's P/E ratio?

Roivant Sciences Ltd's P/E ratio is -126.7.

Roivant Sciences Ltd

NASDAQ · ROIV
$30.04+0.31(+1.04%)Pre-marketNASDAQ regular session 09:30–16:00 ET
Ask about Roivant Sciences Ltd's future dividend policy...
Alpha Chat Insight

Roivant Sciences Ltd trades at a P/E of -126.7 (undervalued) with modest ROE of -3.2%.

Ask for details

Company Overview

Roivant Sciences Ltd is a biopharmaceutical company focused on developing and commercializing innovative therapies through a unique model that emphasizes rapid and efficient drug delivery. As a platform company, Roivant Sciences incubates subsidiaries known as 'Vants,' each concentrating on a specific therapeutic area. This model allows Roivant to prioritize development of pharmaceuticals in critical areas, including neurology, oncology, immunology, and others. Roivant’s approach facilitates agility in drug development, enabling each Vant to operate semi-autonomously to accelerate research and commercialization efforts. By leveraging technology and data analytics, Roivant enhances drug discovery processes and optimizes clinical trials. In the pharmaceutical industry, Roivant Sciences represents a forward-thinking entity that addresses unmet medical needs by transforming the traditional paradigms of drug development. Its initiatives have substantial implications for healthcare, potentially altering treatment landscapes and improving patient outcomes globally. Founded in 2014 and headquartered in New York City, Roivant is a notable example of innovation-driven pharmaceutical enterprise in the financial market.

CEOMr. Matthew Gline
SectorHealthcare
IndustryBiotechnology
Employees750

Company Statistics

FY 2025

Profile

$21.79BMarket Cap
$29.05MRevenue
0.00Shares Out
750Employees

Margins

96.86%Gross
-4365.44%EBITDA
-3833.27%Operating
-2346.02%Pre-Tax
-1227.87%Net

Valuation

-126.71P/E
4.65P/B
750.04EV/Sales
-15.51EV/EBITDA
-25.82P/FCF

Growth (CAGR)

-19.30%Rev 3Yr
N/ARev 5Yr
N/AOp Inc 3Yr
N/AOp Inc 5Yr
N/ANet Inc 3Yr
N/ANet Inc 5Yr

Returns

-5.64%ROA
-3.23%ROE
-17.59%ROIC

Financial Health

$2.72BCash & Cash Equivalents
$-2.47BNet Debt
4.81%Debt/Equity
N/AInterest Cov

Frequently Asked Questions

Roivant Sciences Ltd (ticker: ROIV) is a company listed on NASDAQ in the Healthcare sector (Biotechnology). It has approximately 750 employees. Market cap is $21.8B.

The current price is $30.04 with a P/E ratio of -126.71x and P/B of 4.65x.

ROE is -3.23% and operating margin is -3833.27%. Annual revenue is $29M.

Alpha Lenz
Singapore
Treasurer Pte Ltd | License: 202346277E
9 Straits View Marina One West Tower #05-07 Singapore 018937
contact@treasurer.co.kr
©2026 Treasurer Pte Ltd. All rights reserved.
Roivant Sciences Ltd (ROIV) Stock Forecast 2026 $30.04 — Price, Financials & Analyst Targets | Alpha Lenz